Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Hemophilia and uniQure's AMT-061 with a gene therapy expert

Ticker(s): QURE

Who's the expert?

Institution: Albert Einstein College of Medicine

  • Professor of Hematology & The Eleazar & Feige Reicher Chair in Translational Medicine, Department of Medicine at Albert Einstein.
  • Significant interest in cell and gene therapies with collaborative translational work in hemophilia with AAV vectors.
  • Research focuses on development of liver cell-based therapies and relevant aspects of stem cell biology including understanding mechanisms by which transplanted cells may engraft, proliferate and function in the liver, obtaining insights into cell-cell interactions that may benefit transplanted cells, and addressing the potential of liver cell types for treating major diseases of interest. 

Interview Goal
To get a better understanding of UniQure's technology and potential role in treating hemophilia.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.